These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23144574)

  • 21. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
    Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
    Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy of bone metastases in breast cancer patients--an update.
    Jacobs C; Simos D; Addison C; Ibrahim M; Clemons M
    Expert Opin Pharmacother; 2014 Jun; 15(8):1109-18. PubMed ID: 24673572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer.
    Brodowicz T; Hadji P; Niepel D; Diel I
    Cancer Treat Rev; 2017 Dec; 61():23-34. PubMed ID: 29100167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.
    Steger GG; Bartsch R
    Ther Adv Med Oncol; 2011 Sep; 3(5):233-43. PubMed ID: 21957430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.
    El-Amm J; Freeman A; Patel N; Aragon-Ching JB
    Prostate Cancer; 2013; 2013():210686. PubMed ID: 24069538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting RANKL in metastasis.
    Dougall WC; Holen I; González Suárez E
    Bonekey Rep; 2014; 3():519. PubMed ID: 24795813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
    J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A; Balakumaran A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SEOM guidelines for the treatment of bone metastases from solid tumours.
    Cassinello Espinosa J; González Del Alba Baamonde A; Rivera Herrero F; Holgado Martín E;
    Clin Transl Oncol; 2012 Jul; 14(7):505-11. PubMed ID: 22721794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.
    Polascik TJ
    Drug Des Devel Ther; 2009 Sep; 3():27-40. PubMed ID: 19920919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab for treatment of breast cancer bone metastases and beyond.
    Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
    Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
    LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
    Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approaches for protecting bone health in patients with breast cancer.
    Lüftner D; Niepel D; Steger GG
    Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab in breast cancer.
    Lipton A
    Curr Oncol Rep; 2011 Feb; 13(1):1-4. PubMed ID: 21053109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.